CM/TNS/24/5713 - NHS Framework for Transition products - 1 February 2025

NHS England · awarded 14 January 2025 · delivered in East Midlands

£9.9m Award value £9,867,000
6 Suppliers Recorded as a large business
31 May 2026 Runs until from 1 Feb 2025

Who

BuyerNHS England Runcorn, Cheshire
Suppliers Baxter Healthcare Ltd
Biocon
Dr.Reddy's Laboratories (UK) Limited
Sun Pharma UK Ltd
Thornton and Ross Ltd
Zentiva Pharma UK Ltd
Categorygoods
ClassificationPharmaceutical products CPV 33600000
Notice published21 January 2025

What it is for

Project title: NHS National Framework for Transition products commencing 1 February 2025 Offer reference number: CM/TNS/24/5713 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5713/01 - Eribulin Injection, Bosutinib Tablets and Liraglutide Injection Lot 1 CESW: 01/02/2025 to 31/05/2026 (16 months) Lot 2 LSNE: 01/02/2025 to 31/05/2026 (16 months) Lot 3 NWLN: 01/02/2025 to 31/05/2026 (16 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Read the original award notice on Contracts Finder →

Other contracts from this buyer

1269 awards on file, worth £50.2bn.

Everything NHS England has awarded →

Other contracts won by this supplier

4 awards on file, worth £1.9bn.

Everything Sun Pharma UK Ltd has won →